Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities
Advanced Science · 2025-01 · 12 (4)
DOI: 10.1002/advs.202403936 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 11.12.2024. Verfasst von Mohammad Burhan Uddin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Significant advances in the development of new cancer therapies have given rise to multiple novel therapeutic options in chemotherapy, radiotherapy, immunotherapy, and targeted therapies. Although the development of resistance is often reported along with temporary disease remission, there is often tumor recurrence of an even more aggressive nature. Resistance to currently available anticancer drugs results in poor overall and disease‐free survival rates for cancer patients. There are multiple mechanisms through which tumor cells develop resistance to therapeutic agents. To date, efforts to overcome resistance have only achieved limited success. Epitranscriptomics, especially related to m 6 A RNA modification dysregulation in cancer, is an emerging mechanism for cancer therapy resistance. Here, recent studies regarding the contributions of m 6 A modification and its regulatory proteins to the development of resistance to different cancer therapies are comprehensively reviewed. The promise and potential limitations of targeting these entities to overcome resistance to various anticancer therapies are also discussed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, North South University, Bashundhara, Dhaka, 1229, Bangladesh.
- Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, 11794, USA.
- Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.
ORCID-Profile: Mohammad Burhan Uddin, Chengfeng Yang
Förderung
- NIEHS NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Uddin, M. B., Wang, Z., & Yang, C. (2025). Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Advanced Science, 12(4). https://doi.org/10.1002/advs.202403936
Vancouver
Uddin MB, Wang Z, Yang C. Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities. Advanced Science. 2025;12(4). doi:10.1002/advs.202403936
BibTeX
@article{Uddin2025,
author = {Uddin, Mohammad Burhan and Wang, Zhishan and Yang, Chengfeng},
title = {Epitranscriptomic RNA m 6 A Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {4},
doi = {10.1002/advs.202403936}
}
EUVIMED